Drug Discovery Services Market: Growth, Size, Share, and Trends
Report Code
PH 5682
Published in
Mar, 2025, By MarketsandMarkets™
Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030
USD 27.23 BN
MARKET SIZE, 2030
CAGR 10.7%
(2025-2030)
457
REPORT PAGES
575
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The drug discovery services market is projected to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, at a CAGR of 10.7%. The growth of the drug discovery services market can be attributed to the growing R&D expenditure from drug pharmaceutical and biopharmaceutical companies, the increasing R&D pipeline creating a need for increased analytical testing outsourcing, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development.
KEY TAKEAWAYS
-
By RegionThe North America drug discovery services market accounted for a 48.7% revenue share in 2024.
-
By ProcessBy process, the hit-to-lead identification segment is expected to dominate the market.
-
By TypeBy type of service, the biology services segment is projected to grow at the fastest rate from 2025 to 2030.
-
By Drug TypeBy drug type, the small molecules segment is expected to dominate the market.
-
Key PlayersCompanies like Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany) were identified as some of the star players in the drug discovery services market (global), given their strong market share and service footprint.
-
SMEsCompanies like BioDuro-Sundia (US), Domainex (UK), and Bioascent Discovery Limited (UK), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
Technological advancements, the introduction of new drug discovery techniques, the expiry of patents, and rising demand for specialized testing services among end users are expected to offer growth opportunities to players in this market. Stringent regulations governing drug discovery and animal usage are expected to restrain market growth to a certain extent. The drug discovery services market is facing challenges due to several factors, including reduced R&D budgets in the pharmaceutical sector and economic uncertainties due to the global landscape.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on customers’ business in the drug discovery services market is being reshaped by complexities in therapeutic modalities and pressure to move from target identification to candidate validation faster with higher translational confidence. Core clients—Tier-1/2 pharma, venture-backed and platform biotech companies, and leading academic/translational institutes are shifting spend from individual/silo services integrated, data-rich programs. Their imperatives primarily include compressing cycle times using automation/AI, raise hit quality with fragment + structure-enabled design, validate targets with multi-omics/CRISPR. Achieving these drives their clients’ clients—patients, payers, and regulators—toward faster entry into clinic, higher probability of success, better patient stratification and therapeutic response, quicker approvals for precision assets, and ultimately lower R&D cost per asset through smarter upstream decisions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Growing research & development expenditure in pharma-biotech sector.
-
Growing pipeline of pharmaceutical and biopharmaceutical companies.
RESTRAINTS
Impact
Level
Level
-
Stringent regulations.
OPPORTUNITIES
Impact
Level
Level
-
Technological advancements and new drug discovery techniques.
-
Rising demand for specialized testing services.
CHALLENGES
Impact
Level
Level
-
Economic uncertainties worldwide.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing research & development expenditure in pharma-biotech sector.
Pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products. Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts.
Restraint: Stringent regulations.
Securing safety and efficacy is the prime focus of regulatory authorities during drug approval. Although these approaches help ensure the quality of the products launched in the market, they substantially increase the cost of drug development and the final product. In price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Apart from this, various legislations that ensure the quality of the product (such as GMP) often increase manufacturing costs.
Opportunity: Technological advancements and new drug discovery techniques.
Startups are leveraging big data, AI, and machine learning to automate data processing and solve complex problems much more quickly than traditional data analysis methods. Protai (Israel) uses the technology to build an AI-driven drug discovery platform. Italian startup Netabolics is predicting the effects of new drugs by digitizing human cells. 3D-bioprinting technology is considered a powerful tool for building tissue and organ structures for drug discovery. In general, bioprinting uses a 3D printer to accurately deposit cells and biomaterials into precise geometries to create anatomically correct biological structures.
Challenge: Economic uncertainties worldwide.
Throughout 2023 and 2024, drug discovery services experienced a downturn due to funding cuts in pharmaceutical R&D and economic uncertainties. Drug discovery services market continuing to face the economic uncertainties worldwide, owing to impacts on funding, operations, and workforce stability. For example, global inflation has caused the prices of raw materials and laboratory equipment to ascend, exhausting already tight budgets for small biotechnology companies.
drug-discovery-services-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Multi-target endometriosis discovery alliance leading to multiple clinical candidates (Phase I). Joint early-discovery collaboration where both parties contributed targets and Evotec provided platform capabilities (HTS, medicinal chemistry, biology, DMPK) to generate first-/best-in-class non-hormonal candidates. | De-risked early pipeline with multiple clinical entries; access to an integrated CRO platform for target ID → preclinical candidate; accelerates progress in a complex indication (endometriosis). |
 |
DEL-based hit discovery collaboration (and HitGen). HitGen applies its DNA-Encoded Library platform (hundreds of billions of compounds) to find novel small-molecule leads for Gilead; a separate deal licensed DEL-identified series to Kaken for development | Rapid hit identification from extremely large chemical space; partner-ready IP that can be licensed/advanced; efficient starting points for difficult targets. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The drug discovery services market operates within a complex ecosystem. Many interconnected stakeholders play an important role in each new drug discovery process. This ecosystem includes suppliers of raw materials, service providers, end users, and regulatory bodies working together to ensure the successful discovery of safe and effective drugs. The market includes various types of academic institutions that conduct early-phase research to aid drug commercialization for drug companies. Regulatory bodies, along with CROs, help to ensure that the process follows security and efficacy standards.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Drug Discovery Services Market, By Process
As of 2024, hit-to-lead identification segment held the largest share of the drug discovery services market and will continue leading the market through 2030. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process. Many CROs offer these services to pharmaceutical companies.
Drug Discovery Services Market, By Type
In 2024, biology services segment is expected to grow at the fastest pace during the forecast period. The growth of biology services can be attributed to the advancements in molecular biology and genomics, increasing demand for biologics and targeted therapies, rising R&D investments in the pharmaceutical and biotechnology sectors.
Drug Discovery Services Market, By Drug Type
The small molecules segment is expected to dominate the drug discovery services market through the forecast period. The process of small molecule drug discovery is complex and challenging. Typically, the workflow begins with initial target identification and validation through assay development, high-throughput screening, hit identification, and lead optimization to preclinical candidate selection. High-throughput screening of drug candidates plays an essential role in drug discovery.
Drug Discovery Services Market, By Therapeutic Area
The monoclonal antibodies segment is expected to dominate the antibody discovery services market through 2025 to 2030. The increase in demand for outsourcing the discovery process in this space is attributed to the rapid expansion of next-generation mAbs, including humanized, fully human, and Fc-engineered formats. Additionally, expanding the clinical pipeline of mAbs across oncology, immunology, and infectious diseases has rendered this segment with the highest growth rate .
Drug Discovery Services Market, By End User
As of 2024, the pharmaceutical & biotechnology companies segment dominated the drug discovery services market. This is attributed to the increased outsourcing of early-phase development and clinical testing services. These companies prefer to outsource research activities to boost profit margins, avoid high capital expenditures, and reduce the time required to validate the process and product.
REGION
Asia Pacific to be the fastest growing region in the drug discovery services market during forecast period
Asia Pacific is expected to grow at the fastest pace throughout the forecast period. Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to the expanding pharmaceutical & biopharmaceutical industry, rising number of CROs, implementation of favorable government policies, increasing number of newly established R&D and manufacturing facilities, and the presence of less-stringent regulations for drug discovery processes (especially in terms of using animals for research) in several APAC countries.
drug-discovery-services-market: COMPANY EVALUATION MATRIX
In the drug discovery services key players market matrix, Labcorp (Star) leads with a strong market share and extensive service footprint, supported by its expansive global footprint and ongoing investments in integrated discovery-to-manufacturing platforms. EVOTEC (Emerging Leader) is gaining visibility with its specialized solutions and tailored solutions for antibody discovery. The company's expanding its regional presence and caters to a comprehensive portfolio of service offerings around biology and chemistry services.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Labcorp (US)
- Charles River Laboratories (US)
- Thermo Fisher Scientific Inc. (US)
- WuXi Biologics (China)
- EVOTEC (Germany)
- Eurofins Scientific (Germany)
- Pharmaron (China)
- Syngene International Limited (India)
- Curia Global, Inc. (US)
- Aragen Life Sciences Ltd. (India)
- Jubilant Pharmova Limited (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Selvita (Poland)
- Shanghai Medicilon Inc. (China)
- Viva Biotech (China)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 14.89 Billion |
| Market Forecast in 2030 (Value) | USD 27.23 Billion |
| Growth Rate | CAGR of 10.7% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: drug-discovery-services-market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Analysis | Additional profiles of regional/local players, their market position/share, strategies, and service portfolios | Insights to uncover market gaps and refine differentiation strategies. |
| End User Market Assessment | Comprehensive list of end users typically engaged in discovery, development & manufacturing of biologics (cell therapy, gene therapy) across targeted regions/countries. | Insights on identifying potential customers of drug discovery services |
| Cross-segmental Analysis | Cross-segmental analysis between small molecule drug discovery and type of services such as chemistry and biology services. | Insights on White Spaces & Unmet Needs, interconnections and supply chain opportunities. |
RECENT DEVELOPMENTS
- January 2025 : Charles River Laboratories partnered with NJ Bio, Inc., a contract research organization specializing in integrated chemistry and bioconjugation services, to expedite clients’ antibody drug conjugate (ADC) development from concept to clinic. The strategic alliance combines Charles River’s end-to-end ADC discovery services with NJ Bio’s bioconjugation and manufacturing capabilities.
- April 2024 : Aurigene Pharmaceutical Services Ltd. has introduced Aurigene.AI, an artificial intelligence (AI) and machine learning (ML)-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
- November 2023 : Frontage Holdings Corporation has announced an initiative to form Global Drug Discovery Services within the organization. Global Drug Discovery Services will unify all chemistry, biology, ADME/PK operations, and pharmacology at various subsidiaries.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
41
2
RESEARCH METHODOLOGY
46
3
EXECUTIVE SUMMARY
58
4
PREMIUM INSIGHTS
63
5
MARKET OVERVIEW
Pharma-biotech sector thrives on R&D, outsourcing, and AI-driven drug discovery amid regulatory and economic hurdles.
66
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
BOOMING RESEARCH & DEVELOPMENT EXPENDITURE IN PHARMA-BIOTECH SECTOR
5.2.1.2
GROWING PIPELINE OF PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2.1.3
RISING RESEARCH ON RARE DISEASES AND ORPHAN DRUGS
5.2.1.4
INCREASING RELIANCE ON OUTSOURCING DUE TO COSTLY IN-HOUSE DRUG DEVELOPMENT
5.2.2
RESTRAINTS
5.2.2.1
STRINGENT REGULATIONS
5.2.3
OPPORTUNITIES
5.2.3.1
TECHNOLOGICAL ADVANCEMENTS AND NEW DRUG DISCOVERY TECHNIQUES
5.2.3.2
RISING DEMAND FOR SPECIALIZED TESTING SERVICES
5.2.3.3
PATENT EXPIRY OF KEY BIOLOGICS
5.2.3.4
HIGH GROWTH PROSPECTS IN EMERGING MARKETS
5.2.4
CHALLENGES
5.2.4.1
ECONOMIC UNCERTAINTIES WORLDWIDE
5.2.5
MARKET TRENDS
5.2.5.1
ADOPTION OF AI IN DRUG DISCOVERY
5.2.5.2
INCREASED OUTSOURCING IN EMERGING ECONOMIES
5.2.5.3
CONSOLIDATION OF CONTRACT RESEARCH ORGANIZATIONS
5.2.5.4
INTEGRATED END-TO-END R&D SERVICE OFFERINGS
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4
PRICING ANALYSIS
5.4.1
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
5.4.2
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
5.5
SUPPLY CHAIN ANALYSIS
5.6
VALUE CHAIN ANALYSIS
5.7
ECOSYSTEM ANALYSIS
5.8
INVESTMENT AND FUNDING SCENARIO
5.9
TECHNOLOGY ANALYSIS
5.9.1
KEY TECHNOLOGIES
5.9.1.1
HIGH-THROUGHPUT SCREENING
5.9.1.2
CRISPR GENE EDITING
5.9.1.3
STRUCTURE-BASED DRUG DESIGN/COMPUTER-AIDED DRUG DESIGN
5.9.2
COMPLEMENTARY TECHNOLOGIES
5.9.2.1
AUTOMATED LIQUID HANDLING
5.9.2.2
IN SILICO MODELING
5.9.2.3
PATIENT-DERIVED XENOGRAFTS AND ORGANOIDS
5.9.3
ADJACENT TECHNOLOGIES
5.9.3.1
NANOTECHNOLOGY
5.9.3.2
SYNTHETIC BIOLOGY
5.9.3.3
ORGAN-ON-A-CHIP TECHNOLOGY
5.10
PATENT ANALYSIS
5.11
KEY CONFERENCES AND EVENTS, 2025–2026
5.12
REGULATORY LANDSCAPE
5.12.1
REGULATORY FRAMEWORK
5.12.1.1
NORTH AMERICA
5.12.1.2
EUROPE
5.12.1.3
ASIA PACIFIC
5.12.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13
PORTER’S FIVE FORCES ANALYSIS
5.13.1
BARGAINING POWER OF SUPPLIERS
5.13.2
BARGAINING POWER OF BUYERS
5.13.3
THREAT OF NEW ENTRANTS
5.13.4
THREAT OF SUBSTITUTES
5.13.5
INTENSITY OF COMPETITIVE RIVALRY
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2
KEY BUYING CRITERIA, BY END USER
5.15
IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
5.15.1
INTRODUCTION
5.15.2
MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
5.15.3
AI USE CASES
5.15.4
FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET
6
DRUG DISCOVERY SERVICES MARKET, BY PROCESS
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 36 Data Tables
113
6.1
INTRODUCTION
6.2
TARGET SELECTION
6.2.1
INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
6.3
TARGET VALIDATION
6.3.1
INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
6.4
HIT-TO-LEAD IDENTIFICATION
6.4.1
RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
6.5
LEAD OPTIMIZATION
6.5.1
NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
6.6
CANDIDATE VALIDATION
6.6.1
GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET
7
DRUG DISCOVERY SERVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 59 Data Tables
132
7.1
INTRODUCTION
7.2
CHEMISTRY SERVICES
7.2.1
SYNTHETIC CHEMISTRY SERVICES
7.2.1.1
INCREASING RELIANCE ON NOVEL AND EFFICIENT SYNTHETIC ROUTES TO AUGMENT GROWTH
7.2.2
ANALYTICAL CHEMISTRY SERVICES
7.2.2.1
RISING DEMAND FOR HIGH-QUALITY, SAFE, AND EFFECTIVE DRUGS TO SUPPORT GROWTH
7.2.3
OTHER CHEMISTRY SERVICES
7.3
BIOLOGY SERVICES
7.3.1
IN VITRO PROFILING SERVICES
7.3.1.1
NEED FOR HIGHER PROJECT PRODUCTIVITY TO SPEED UP GROWTH
7.3.2
TOXICOLOGY SERVICES
7.3.2.1
GROWING EMPHASIS ON ASSESSING SAFETY PROFILES OF NEW DRUG CANDIDATES TO PROPEL MARKET
7.3.3
OTHER BIOLOGY SERVICES
8
DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
159
8.1
INTRODUCTION
8.2
SMALL MOLECULES
8.2.1
INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
8.3
BIOLOGICS
8.3.1
GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET
9
DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 76 Data Tables
168
9.1
INTRODUCTION
9.2
ONCOLOGY
9.2.1
GROWING INCIDENCE OF CANCER TO PROPEL MARKET
9.3
INFECTIOUS DISEASES
9.3.1
RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
9.4
CARDIOVASCULAR DISEASES
9.4.1
HIGH MORTALITY RATES TO SPUR GROWTH
9.5
NEUROLOGICAL DISEASES
9.5.1
INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
9.6
IMMUNOLOGICAL DISORDERS
9.6.1
GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
9.7
ENDOCRINE & METABOLIC DISORDERS
9.7.1
BOOMING DIABETIC POPULATION TO AID GROWTH
9.8
RESPIRATORY DISORDERS
9.8.1
RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
9.9
DIGESTIVE SYSTEM DISEASES
9.9.1
CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
9.10
GENITOURINARY DISEASES & WOMEN’S HEALTH
9.10.1
RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
9.11
OTHER THERAPEUTIC AREAS
10
DRUG DISCOVERY SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 45 Data Tables
204
10.1
INTRODUCTION
10.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1
TIER 1 COMPANIES
10.2.1.1
RISING RESEARCH & DEVELOPMENT ACTIVITIES TO SUSTAIN GROWTH
10.2.2
TIER 2 COMPANIES
10.2.2.1
GROWING FOCUS ON SPECIFIC THERAPEUTIC AREAS TO DRIVE MARKET
10.2.3
TIER 3 COMPANIES
10.2.3.1
INCREASING SPECIALIZED DRUG DISCOVERY PROJECTS TO EXPEDITE GROWTH
10.3
ACADEMIC INSTITUTES
10.3.1
INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
10.4
OTHER END USERS
11
DRUG DISCOVERY SERVICES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 237 Data Tables.
224
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK OF NORTH AMERICA
11.2.2
US
11.2.2.1
GLOBAL LEADERSHIP IN PHARMACEUTICAL AND BIOPHARMACEUTICAL RESEARCH TO AID GROWTH
11.2.3
CANADA
11.2.3.1
INCREASING INITIATIVES FOR COMMERCIALIZING DRUGS TO STIMULATE GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK OF EUROPE
11.3.2
GERMANY
11.3.2.1
RISING DOMINANCE OF CONTRACT RESEARCH ORGANIZATIONS TO ENCOURAGE GROWTH
11.3.3
UK
11.3.3.1
INCREASING GOVERNMENT-PRIVATE SECTOR COLLABORATIONS TO BOOST MARKET
11.3.4
FRANCE
11.3.4.1
GROWING NUMBER OF ONCOLOGY RESEARCH PROJECTS TO PROPEL MARKET
11.3.5
ITALY
11.3.5.1
HIGH NUMBER OF CLINICAL TRIALS AND LOW DRUG APPROVAL TIME TO PROMOTE GROWTH
11.3.6
SPAIN
11.3.6.1
RISING ELDERLY POPULATION TO INTENSIFY GROWTH
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK OF ASIA PACIFIC
11.4.2
CHINA
11.4.2.1
BOOMING PHARMACEUTICAL INDUSTRY TO SUSTAIN GROWTH
11.4.3
JAPAN
11.4.3.1
INCREASING GERIATRIC POPULATION TO SUPPORT GROWTH
11.4.4
INDIA
11.4.4.1
GROWING FOREIGN DIRECT INVESTMENTS TO DRIVE MARKET
11.4.5
SOUTH KOREA
11.4.5.1
FAVORABLE GOVERNMENT SUPPORT TO ACCELERATE GROWTH
11.4.6
AUSTRALIA
11.4.6.1
RISING NUMBER OF CLINICAL TRIALS TO FOSTER GROWTH
11.4.7
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK OF LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
REDUCED TIMELINE FOR DRUG APPROVALS TO FAVOR GROWTH
11.5.3
MEXICO
11.5.3.1
FAVORABLE GOVERNMENT POLICIES TO INTENSIFY GROWTH
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2
GCC COUNTRIES
11.6.2.1
SAUDI ARABIA
11.6.2.2
UAE
11.6.2.3
OTHER GCC COUNTRIES
11.6.3
REST OF MIDDLE EAST
11.7
AFRICA
11.7.1
RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
11.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
12
COMPETITIVE LANDSCAPE
Discover how key players dominate the drug discovery market through strategic innovations and market share.
340
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
12.3
REVENUE ANALYSIS, 2020−2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY VALUATION AND FINANCIAL METRICS
12.6
BRAND/SERVICE COMPARISON
12.6.1
THERMO FISHER SCIENTIFIC INC. (US)
12.6.2
CHARLES RIVER LABORATORIES (US)
12.6.3
LABCORP (US)
12.6.4
WUXI APPTEC (CHINA)
12.6.5
PHARMARON (CHINA)
12.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1
STARS
12.7.2
EMERGING LEADERS
12.7.3
PERVASIVE PLAYERS
12.7.4
PARTICIPANTS
12.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1
COMPANY FOOTPRINT
12.7.5.2
REGION FOOTPRINT
12.7.5.3
PROCESS FOOTPRINT
12.7.5.4
TYPE FOOTPRINT
12.7.5.5
THERAPEUTIC AREA FOOTPRINT
12.7.5.6
DRUG TYPE FOOTPRINT
12.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1
PROGRESSIVE COMPANIES
12.8.2
RESPONSIVE COMPANIES
12.8.3
DYNAMIC COMPANIES
12.8.4
STARTING BLOCKS
12.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES
12.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
12.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.9
COMPETITIVE SCENARIO
12.9.1
SERVICE LAUNCHES
12.9.2
DEALS
12.9.3
EXPANSIONS
12.9.4
OTHER DEVELOPMENTS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
367
13.1
KEY PLAYERS
13.1.1
THERMO FISHER SCIENTIFIC INC.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
SERVICES OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
CHARLES RIVER LABORATORIES
13.1.3
WUXI APPTEC
13.1.4
PHARMARON
13.1.5
LABCORP
13.1.6
EVOTEC
13.1.7
SYNGENE INTERNATIONAL LIMITED
13.1.8
EUROFINS SCIENTIFIC
13.1.9
JUBILANT PHARMOVA LIMITED
13.1.10
GENSCRIPT
13.1.11
FRONTAGE HOLDINGS CORPORATION
13.1.12
PIRAMAL ENTERPRISES LTD.
13.1.13
AURIGENE PHARMACEUTICAL SERVICES LTD.
13.1.14
CURIA GLOBAL, INC.
13.1.15
SHANGHAI MEDICILON INC.
13.1.16
SYGNATURE DISCOVERY
13.2
OTHER PLAYERS
13.2.1
SELVITA
13.2.2
VIVA BIOTECH
13.2.3
TCG LIFESCIENCES PVT. LTD.
13.2.4
SHANGHAI CHEMPARTNER
13.2.5
DOMAINEX
13.2.6
NUVISAN GMBH
13.2.7
DALTON PHARMA SERVICES
13.2.8
ARAGEN LIFE SCIENCES LTD.
13.2.9
ONCODESIGN SERVICES
14
APPENDIX
442
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
DRUG DISCOVERY SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3
DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS
TABLE 4
DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5
US: BIOLOGICS GOING OFF PATENT, 2025–2030
TABLE 6
DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021–2024
TABLE 7
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
TABLE 8
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
TABLE 9
DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10
INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025
TABLE 11
DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024
TABLE 12
DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 13
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 18
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 19
KEY BUYING CRITERIA, BY END USER
TABLE 20
KEY COMPANIES IMPLEMENTING AI
TABLE 21
DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 22
DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 23
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 24
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 28
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 30
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 35
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 37
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 44
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 49
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 56
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 58
DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 59
DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
NORTH AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
EUROPE: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
ASIA PACIFIC: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
LATIN AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
MIDDLE EAST: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 72
GCC COUNTRIES: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 74
NORTH AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
EUROPE: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
ASIA PACIFIC: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
LATIN AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
MIDDLE EAST: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 79
GCC COUNTRIES: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
NORTH AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
EUROPE: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
ASIA PACIFIC: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
LATIN AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
MIDDLE EAST: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
GCC COUNTRIES: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 88
DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 94
GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
GCC COUNTRIES: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 103
NORTH AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
EUROPE: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
ASIA PACIFIC: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
LATIN AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
MIDDLE EAST: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
GCC COUNTRIES: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 110
NORTH AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
EUROPE: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
ASIA PACIFIC: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
LATIN AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
MIDDLE EAST: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
GCC COUNTRIES: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 117
DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 118
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 123
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 125
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 130
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 132
LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2024
TABLE 133
DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 141
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES, 2024
TABLE 148
DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 149
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 154
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS, 2024
TABLE 156
DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 157
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 162
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2024
TABLE 164
DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 165
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171
DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 172
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 177
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178
LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2024
TABLE 179
DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 180
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 185
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 187
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 192
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)
TABLE 194
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)
TABLE 199
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200
DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 201
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 206
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207
DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 208
DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 209
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 214
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215
DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 216
TOP REVENUE-GENERATING PHARMA COMPANIES, 2023
TABLE 217
DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 218
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 223
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224
DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 225
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 227
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 229
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 230
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231
DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 232
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 236
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 237
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 238
DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 239
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 241
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 242
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 243
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 244
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 245
DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 246
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 247
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 249
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 250
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 251
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 252
DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 253
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 254
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 255
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 256
NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 257
NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 259
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 260
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 261
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262
KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
TABLE 263
US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 264
US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 265
US: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 266
US: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 268
US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 269
US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 270
US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 271
CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 272
CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273
CANADA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 274
CANADA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275
CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 276
CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 277
CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 278
CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 279
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 280
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 281
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 282
EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283
EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 284
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 285
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 286
EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 287
EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
KEY MACROECONOMIC INDICATORS OF EUROPE
TABLE 289
GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 290
GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291
GERMANY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 292
GERMANY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 293
GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 294
GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 295
GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 296
GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 297
UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 298
UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299
UK: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300
UK: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 302
UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 303
UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 304
UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 305
FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 306
FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307
FRANCE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 308
FRANCE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 309
FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 310
FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 311
FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 312
FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 313
ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 314
ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
ITALY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 316
ITALY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 317
ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 318
ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 319
ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 320
ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321
SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 322
SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 323
SPAIN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324
SPAIN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 325
SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 326
SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 327
SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 328
SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 330
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 331
REST OF EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 332
REST OF EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 333
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 334
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 335
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 336
REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 338
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 339
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340
ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 341
ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 342
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 343
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 344
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 345
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 346
KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
TABLE 347
CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 348
CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 349
CHINA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 350
CHINA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 351
CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 352
CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 353
CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 354
CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 355
JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 356
JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 357
JAPAN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 358
JAPAN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359
JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 360
JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 361
JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 362
JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 363
INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 364
INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 365
INDIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 366
INDIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367
INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 368
INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 369
INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 370
INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 371
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 372
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 373
SOUTH KOREA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 374
SOUTH KOREA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 375
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 376
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 377
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 378
SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 379
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 380
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381
AUSTRALIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 382
AUSTRALIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 383
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 384
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 385
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 386
AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 387
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 388
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 389
REST OF ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 390
REST OF ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 391
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 392
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 393
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 394
REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 395
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 396
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 397
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 398
LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 399
LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 400
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 401
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 402
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 403
LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 404
KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
TABLE 405
BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 406
BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 407
BRAZIL: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 408
BRAZIL: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 409
BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 410
BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 411
BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 412
BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 413
MEXICO: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 414
MEXICO: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 415
MEXICO: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 416
MEXICO: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 417
MEXICO: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 418
MEXICO: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 419
MEXICO: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 420
MEXICO: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 421
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 422
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 423
REST OF LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 424
REST OF LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 425
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 426
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 427
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 428
REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 429
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 430
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 431
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 432
MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 433
MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 434
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 435
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 436
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 437
MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 438
KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
TABLE 439
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 440
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 441
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 442
GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 443
GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 444
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 445
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 446
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 447
GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 448
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 449
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 450
SAUDI ARABIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 451
SAUDI ARABIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 452
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 453
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 454
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 455
SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 456
UAE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 457
UAE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 458
UAE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 459
UAE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 460
UAE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 461
UAE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 462
UAE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 463
UAE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 464
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 465
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 466
OTHER GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 467
OTHER GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 468
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 469
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 470
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 471
OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 472
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 473
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 474
REST OF MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 475
REST OF MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 476
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 477
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 478
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 479
REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 480
AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 481
AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 482
AFRICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 483
AFRICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 484
AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
TABLE 485
AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 486
AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 487
AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 488
KEY MACROECONOMIC INDICATORS OF AFRICA
TABLE 489
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021−2024
TABLE 490
DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 491
DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT
TABLE 492
DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT
TABLE 493
DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT
TABLE 494
DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 495
DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT
TABLE 496
DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 497
DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 498
DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 499
DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025
TABLE 500
DRUG DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 501
DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 502
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 503
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 504
THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 505
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 506
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 507
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 508
CHARLES RIVER LABORATORIES: SERVICES OFFERED
TABLE 509
CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 510
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025
TABLE 511
WUXI APPTEC: COMPANY OVERVIEW
TABLE 512
WUXI APPTEC: SERVICES OFFERED
TABLE 513
WUXI APPTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 514
PHARMARON: COMPANY OVERVIEW
TABLE 515
PHARMARON: SERVICES OFFERED
TABLE 516
PHARMARON: DEALS, JANUARY 2021–JANUARY 2025
TABLE 517
LABCORP: COMPANY OVERVIEW
TABLE 518
LABCORP: SERVICES OFFERED
TABLE 519
LABCORP: DEALS, JANUARY 2021–JANUARY 2025
TABLE 520
LABCORP: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 521
EVOTEC: COMPANY OVERVIEW
TABLE 522
EVOTEC: SERVICES OFFERED
TABLE 523
EVOTEC: DEALS, JANUARY 2021–JANUARY 2025
TABLE 524
EVOTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 525
EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 526
SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 527
SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
TABLE 528
SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021–JANUARY 2025
TABLE 529
SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 530
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 531
EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 532
EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 533
EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–JANUARY 2025
TABLE 534
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 535
JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW
TABLE 536
JUBILANT PHARMOVA LIMITED: SERVICES OFFERED
TABLE 537
JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021–JANUARY 2025
TABLE 538
JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 539
GENSCRIPT: COMPANY OVERVIEW
TABLE 540
GENSCRIPT: SERVICES OFFERED
TABLE 541
GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 542
GENSCRIPT: DEALS, JANUARY 2021–JANUARY 2025
TABLE 543
FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 544
FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED
TABLE 545
FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 546
FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021–JANUARY 2025
TABLE 547
FRONTAGE HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 548
PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW
TABLE 549
PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED
TABLE 550
PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 551
DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
TABLE 552
AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
TABLE 553
AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 554
AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 555
AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 556
CURIA GLOBAL, INC.: COMPANY OVERVIEW
TABLE 557
CURIA GLOBAL, INC.: SERVICES OFFERED
TABLE 558
CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
TABLE 559
CURIA GLOBAL, INC.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 560
CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 561
SHANGHAI MEDICILON INC.: COMPANY OVERVIEW
TABLE 562
SHANGHAI MEDICILON INC.: SERVICES OFFERED
TABLE 563
SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 564
SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 565
SYGNATURE DISCOVERY: COMPANY OVERVIEW
TABLE 566
SYGNATURE DISCOVERY: SERVICES OFFERED
TABLE 567
SYGNATURE DISCOVERY: DEALS, JANUARY 2021–JANUARY 2025
TABLE 568
SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 569
SELVITA: COMPANY OVERVIEW
TABLE 570
VIVA BIOTECH: COMPANY OVERVIEW
TABLE 571
TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 572
SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
TABLE 573
DOMAINEX: COMPANY OVERVIEW
TABLE 574
NUVISAN GMBH: COMPANY OVERVIEW
TABLE 575
DALTON PHARMA SERVICES: COMPANY OVERVIEW
TABLE 576
ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
TABLE 577
ONCODESIGN SERVICES: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
DRUG DISCOVERY SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
DRUG DISCOVERY SERVICES MARKET: YEARS CONSIDERED
FIGURE 3
DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
FIGURE 5
GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION, 2024
FIGURE 6
COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
FIGURE 7
REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
FIGURE 8
MARKET SIZE VALIDATION FROM PRIMARIES
FIGURE 9
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 10
DRUG DISCOVERY SERVICES MARKET: CAGR PROJECTIONS, 2025–2030
FIGURE 11
DRUG DISCOVERY SERVICES MARKET: DATA TRIANGULATION
FIGURE 12
DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2025 VS. 2030 (USD MILLION)
FIGURE 13
DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 14
DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 15
DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030
FIGURE 16
DRUG DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025–2030
FIGURE 18
INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET
FIGURE 19
SMALL MOLECULES SEGMENT AND US LED NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2024
FIGURE 20
CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 21
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
FIGURE 22
DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23
GLOBAL PHARMACEUTICAL R&D SPENDING, 2016–2030
FIGURE 24
ACTIVE PHARMACEUTICAL PIPELINE, 2014–2024
FIGURE 25
NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013–2023
FIGURE 26
AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013–2023 (USD BILLION)
FIGURE 27
NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET
FIGURE 28
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
FIGURE 29
INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
FIGURE 30
DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 31
DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 32
DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 33
INVESTMENT AND FUNDING SCENARIO, 2022–2025
FIGURE 34
DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014–2024
FIGURE 35
DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 36
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 37
KEY BUYING CRITERIA, BY END USER
FIGURE 38
AI USE CASES
FIGURE 39
ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
FIGURE 40
NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
FIGURE 41
DISTRIBUTION OF PHARMACEUTICAL R&D COMPANIES, BY COUNTRY/REGION, 2023 VS. 2024
FIGURE 42
ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
FIGURE 43
REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020−2024
FIGURE 44
MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024
FIGURE 45
RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024
FIGURE 46
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
FIGURE 47
EV/EBITDA OF KEY PLAYERS, 2024
FIGURE 48
DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARISON
FIGURE 49
DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 50
DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 51
DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 52
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 53
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
FIGURE 54
WUXI APPTEC: COMPANY SNAPSHOT (2023)
FIGURE 55
PHARMARON: COMPANY SNAPSHOT (2023)
FIGURE 56
LABCORP: COMPANY SNAPSHOT (2023)
FIGURE 57
EVOTEC: COMPANY SNAPSHOT (2023)
FIGURE 58
SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023)
FIGURE 59
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 60
JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023)
FIGURE 61
GENSCRIPT: COMPANY SNAPSHOT (2023)
FIGURE 62
FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 63
PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023)
FIGURE 64
DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)
Methodology
The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery services market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery services market, which was further validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies.
Stakeholders
- Drug discovery service providers
- Pharmaceutical and biotechnology companies
- Academic & Research Institutes
- Contract Research Organization
- Market Research and Consulting Firms
- R&D Centers
- Researchers and Scientists
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the drug discovery services market by value by process, type, drug type, therapeutic area, end user and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery services market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Drug Discovery Services Market